Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
Public ClinicalTrials.gov record NCT05359861. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With CHS-388 (Formerly Known as SRF388) or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a Phase 2 trial composed of an open label Lead-In followed by a planned Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC. Only the Lead-In Phase of the study was completed.
Study identification
- NCT ID
- NCT05359861
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 12, 2022 (Actual)
- Primary completion
- Jun 30, 2025 (Actual)
- Completion
- Jul 8, 2025 (Actual)
- Last update posted
- Oct 1, 2026
2022 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Arizona Cancer Center - North Campus | Tucson | Arizona | 85719 | — |
| City of Hope | Duarte | California | 91010 | — |
| University of Southern California - Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | — |
| University of Florida Health Science Center - Gainesville | Gainesville | Florida | 32610 | — |
| University of Miami, Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| Louisville VA Medical Center - Robley Rex VA Medical Center | Louisville | Kentucky | 40206 | — |
| Veterans Affairs Ann Arbor Healthcare System | Ann Arbor | Michigan | 48105 | — |
| University of Michigan Health System (UMHS) | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Veterans Affairs New York Harbor Healthcare System - Manhattan VA Medical Center | New York | New York | 10010 | — |
| NYU Langone Medical Center - Laura and Isaac Perlmutter Cancer Center (NYU Cancer Institute (NYUCI)) | New York | New York | 10016 | — |
| University of Oklahoma Health Sciences Center - Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Research Institute - Tennessee Oncology | Nashville | Tennessee | 37203 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05359861, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 1, 2026 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05359861 live on ClinicalTrials.gov.